Observational Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Mar 28, 2018; 24(12): 1353-1360
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1353
Table 1 Baseline characteristics of study cohort n (%)
CharacteristicData
SexMale28 (71.8)
Female11 (28.2)
Age (yr)58.6 (range: 45.8-72.3)
ImmunosuppressionCyclosporine19 (48.7)
Tacrolimus18 (46.2)
Sirolimus1 (2.6)
Everolimus1 (2.6)
Mycophenolate mofetil21 (53.8)
Liver histologyF0-27 (17.9)
F315 (38.5)
F417 (43.6)
Liver function, CTPA17 (43.6)
B2 (5.1)
Risk factorsInterferon-experienced29 (74.4)
History of HCC26 (66.7)
HCV genotype124 (61.5)
21 (2.6)
313 (33.3)
41 (2.6)
Table 2 Hepatitis C virus treatment regimens
nTherapySVR24
5IFN + SOF + RBV4/5 (80.0%)
8SOF + RBV6/8 (75.0%)
9DAC +SOF + RBV9/9 (100.0%)
1DAC + SOF1/1 (100.0%)
13LDV + SOF + RBV13/13 (100.0%)
2LDV + SOF2/2 (100.0%)
1SIM + SOF + RBV1/1 (100.0%)
Table 3 Viral load throughout treatment period
Time (wk)MeanMinMax
T (0)32687704560025200000
T (4)25812.10771000
T (8)22.80268
T (12)4.10101
T (24)000